Cancer Incidence in C3H Mice Protected from Lethal Total-Body Radiation after Amifostine.

Abstract

Amifostine is a potent antioxidant that protects against ionizing radiation effects. In this study, we evaluated the effect of Amifostine administered before total-body irradiation (TBI), at a drug dose that protects against TBI lethality, for potential protection against radiation-induced late effects such as a shortened lifespan and cancer. Three groups of mice were studied: 0 Gy control; 10.8 Gy TBI with Amifostine pretreatment; and 5.4 Gy TBI alone. Animals were monitored for their entire lifespan. The median survival times for mice receiving 0, 5.4 or 10.8 Gy TBI were 706, 460 and 491 days, respectively. Median survival of both irradiated groups was significantly shorter compared to nonirradiated mice ( P < 0.0001). Cancer incidence (hematopoietic and solid tumors) was similar between the irradiated groups and was significantly greater than for the 0 Gy controls. The ratio of hematopoietic-to-solid tumors differed among the groups, with the 5.4 Gy group having a higher incidence of hematopoietic neoplasms compared to the 10.8 Gy/Amifostine group (1.8-fold). Solid tumor incidence was greater in the 10.8 Gy/Amifostine group (1.6-fold). There are few mouse lifespan studies for agents that protect against radiation-induced lethality. Mice treated with 10.8 Gy/Amifostine yielded a lower incidence of hematopoietic neoplasms and higher incidence of solid neoplasms. In conclusion, mice protected from lethal TBI have a shortened lifespan, due in large part to cancer induction after exposure compared to nonexposed controls. Amifostine treatment did protect against radiation-induced hematopoietic tumors, while protection against solid neoplasms was significant but incomplete.

• Authors: John A Cook, Sarwat Naz, Miriam R Anver, Anastasia L Sowers, Kristin Fabre, Murali C Krishna, James B Mitchell
• Journal: Radiation research (Radiat Res) Vol. 189 Issue 5 Pg. 490-496 (05 2018) ISSN: 1938-5404 [Electronic] United States
• PMID: 29528769 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural)

Chemical References

• Radiation-Protective Agents
• Amifostine

Topics

• Amifostine (pharmacology)
• Animals
• Carcinogenesis (drug effects, radiation effects)
• Dose-Response Relationship, Radiation
• Female
• Mice
• Neoplasms, Radiation-Induced (etiology, prevention & control)
• Radiation-Protective Agents (pharmacology)
• Whole-Body Irradiation (adverse effects)